The EPS miss is notable but secondary to the barzolvolimab pipeline catalyst. The Phase 3 topline readout in Q4 2026 is the primary value driver. Traders should monitor for any safety signals or enrollment updates ahead of that date. The stock may trade on pipeline sentiment rather than quarterly financials in the near term.
Price Chart
Executive Summary
Celldex reported Q1 2026 EPS of -$1.18, missing consensus of -$1.07 by 10.8%. The press release focuses on positive long-term Phase 2 data for barzolvolimab in CSU, showing durable angioedema improvements off-treatment through Week 76. Phase 3 topline data is expected in Q4 2026, with a BLA submission planned for 2027.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$1.18 missed consensus of -$1.07 (-10.8% miss)
- Revenue of $859K (consensus $859K) — in line
- Phase 2 barzolvolimab data showed up to 64% of angioedema patients remained symptom-free 7 months after last dose
- Phase 3 CSU trials fully enrolled with 1,939 patients; topline data expected Q4 2026
- BLA submission planned for 2027
- No revenue guidance or financial outlook provided
Financial Impact
EPS miss of $0.11 per share vs consensus; no revenue surprise
Risk Factors
- Phase 3 barzolvolimab data may fail to replicate Phase 2 efficacy or show unexpected safety issues
- No approved products or recurring revenue; cash burn continues with no near-term commercialization
- Competition from existing CSU therapies (omalizumab, ligelizumab) could limit market opportunity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311449 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 14, 2026 15w ago | Press Release | $32.12 $38.53 | ▼ −19.96% | ▼ −20.71% | $31.22 (+2.82%) |
Jun 14, 2026 15w ago | Press Release | $32.12 $38.53 | ▲ +19.96% | ▲ +20.71% | $31.22 (−2.82%) |
Jun 11, 2026 16w ago | Institutional Cluster | $29.96 $38.98 | ▲ +30.11% | ▲ +28.22% | $31.22 (+4.19%) |
Jun 10, 2026 16w ago | Press Release | $29.96 $38.98 | ▲ +30.11% | ▲ +28.22% | $31.22 (+4.19%) |
May 7, 2026 21w ago | 8-K | $33.97 $28.62 | ▼ −15.75% | ▼ −15.77% | $31.22 (−8.11%) |
May 7, 2026 21w ago | Press Release | $33.97 $28.62 | ▼ −15.75% | ▼ −15.77% | $31.22 (−8.11%) |
Apr 6, 2026 25w ago | Press Release | $31.37 $32.77 | ▲ +4.46% | ▼ −4.52% | $31.22 (−0.49%) |
Apr 2, 2026 26w ago | Press Release | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $31.22 (+0.50%) |
Apr 1, 2026 26w ago | 424B5 | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $31.22 (+0.50%) |
Apr 1, 2026 26w ago | Press Release | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $31.22 (+0.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access